Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : News that catches your eye -- Ignore unavailable to you. Want to Upgrade?

To: FARcom who wrote (113)	2/3/1999 5:35:00 PM
From: John Fairchild	Read Replies (1) \| Respond to of 148

IMM-V Immune Network. NR issued late in the day saw an immediate market response. This company has been testing a new HIV/AIDS antibody which has shown very good results in Phase I testing on monkeys (increased immune levels). The phase II study (now complete with assays now in the lab) will determine viral load. In phase II they hit the monkeys with extremely high dosage and expected to see some die or at least get very sick. It did not happen, the monkeys stayed healthy. After the test these monkeys went to Harvard University. If you check out the web site you will see that the doctors behind this discovery are leading experts in this field with much research to their credit. This antibody may have many applications "silver bullet". Investors have been waiting months for this testing to commence with many becoming impatient and selling it down (bottomed out at .09 before the announcement). The company could have begun testing months ago with another lab but was waiting for acceptance by one which would provide recognition and future synergies and they have found it in the ' United States National Cancer Institute laboratory". I have a core holding in this stock but have played it since last summer and have witnessed how quickly it can take off. Assay results should take about two week. immunenetwork.com Immune Network Research Ltd - Immune Network progress on phase II study, private placement Immune Network Research Ltd IMMShares issued 20,370,4521999-02-02 close $0.1Wednesday Feb 3 1999VANCOUVER, B.C. - The Company is very pleased to announce that arrangements have been made to test the plasma samples from the Phase II macaque study of the Company's patented monoclonal antibody 1F7 (mAb 1F7). These tests of the biological efficacy of antiviral immunity induced or restored by mAb 1F7 will use a highly sensitive polymerase chain reaction-based assay to determine the viral load in plasma samples from SHIV-infected monkeys. Arrangements for these tests were made by Immpheron, Inc., the Company's research partner on the project, through a collaboration with researchers at Harvard University. This collaboration will enable the plasma tests to be performed at the United States National Cancer Institute laboratory, part of the National Institute of Health. The Phase II study involved nine macaques, which are a recognized model of HIV disease in humans, observed over a period of over six months and treated with two series of injections with mAb 1F7. Results of the tests are to form part of the Company's intended application to the FDA for a clinical trial of mAb 1F7 as an Investigational New Drug. In a related study, research has commenced on lymph node samples from selected macaques in collaboration with researchers at Duke University Medical Centre. This study will investigate B-cell response to mAb 1F7. In the Phase I macaque study mAb 1F7 appeared to strengthen the immune response and may play a role by inducing the immune system to produce antibodies of different specificity. Research is ongoing into the mechanism of the patented mAb 1F7 through an evaluation of the virus neutralizing antibody levels observed in the earlier Phase I macaque study. A manuscript by Dr. Sybille Muller, Vice President of Immpheron and Director of the Company's research program, has been submitted to a recognized journal in the field of immunology and AIDS. On corporate matters, the Company has received regulatory approval for the private placement of $54,000 and the issue of 360,000 shares together with one year warrants for the purchase of an additional 180,000 shares all at a price of $0.15 per share. The Company concluded its arrangement with an investor relations firm at the end of last year. Victor J.E. Jones President THE VANCOUVER STOCK EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE. Immune Network Research Ltd. 900 - 475 Howe St, Vancouver, BC, Canada V6C 2B3 Tel. (604) 689-3923 * Fax. (604) 684-5854 www.immunenetwork.com (c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com